Table 2.

Association between serum IL-6 concentrations and flavonol intake during the trial (n = 872)

IL-6 (pg/mL)Flavonol intake quartiles (mg/d)*P
Q1: <21.2Q2: 21.2-29.7Q3: 29.8-40.0Q4: >40.0
Median (IQR)Median (IQR)Median (IQR)Median (IQR)
Sample size218218218218
Baseline (T0)2.02 (1.41-2.99)1.90 (1.38-2.97)1.79 (1.32-2.75)1.95 (1.31-2.69)0.30
Year 1 (T1)2.05 (1.41-3.23)2.00 (1.37-3.00)1.77 (1.26-2.46)1.83 (1.26-2.72)0.008
Year 3 (T3)2.30 (1.62-3.46)2.07 (1.58-3.25)1.99 (1.41-2.76)1.84 (1.35-2.64)0.0002
Trial (T1,3)2.20 (1.61-3.19)2.07 (1.54-2.98)1.84 (1.37-2.51)1.80 (1.39-2.60)0.0002
Change (T1,3-T0)0.17 (−0.30-0.60)0.19 (−0.54-0.67)−0.01 (−0.40-0.44)0.01 (−0.51-0.48)0.07
  • *Participants were grouped in quartiles (Q1-Q4) by mean flavonol intake during the first 3 trial years.

  • P values for differences in medians among the flavonol intake quartiles were calculated based on the Kruskal-Wallis test. The P value for trend using a multiple regression model adjusting for age tertiles (<58, 58-66, >66 y), sex, average BMI (<25, 25.0-29.9, ≥30 kg/m2), current smoking status, and average energy intake (continuous) during the first 3 trial years was 0.01 for Trial (T1,3) and 0.10 for Change (T1,3-T0).

  • Trial (T1,3) = geometric mean of year 1 and year 3 values. Change (T1,3-T0) = T1,3 minus baseline values.